Table IV.

Comparison of peripheral vs tumor site monitoring after 209-2M-based peptide vaccinationa

PatientTherapyPeripheral Monitoring (PBMC)Tumor Monitoring (Tumor Aspirates)Tumor Response Size (cm)
IVSNo pep209-paFold incTumor siteNo pepbFold inccgp100d
1Pre(−)54641.2Right axilla5681,2424
Post(+)471032.27,58613.41,3109
2Pre(−)39451.2Left thigh3311,9561
Post(−)41431.011,86535.83,9551
3Pre(−)22241.1Right axilla1,1876,1869
Post(−)30451.57,8916.661125
4Pre(−)52280.5Left thigh5792,8656
Post(−)35371.17,78813.589420.25
5Pre(−)104920.9Right thigh2,2311,2261
Post(+)50721.44,4522.02354
6Pre(−)95840.9Left chest1,01312
Post(+)421513.65,5325.5185
7Pre(−)59440.7#1 left medial knee3,24702.25
Post(−)29371.31,6490.512.5
#2 left lateral knee2,86516.25
2,1310.716.25
8Pre(−)73690.9#1 right lower thigh1404,7866
Post(−)1101481.31,58511.32,2914
#2 right upper thigh46653216
7591.631216
9Pre(−)1031071.0Right groin692604
Post(+)675468.11,4742.1126
  • a Preimmunization PBMC samples were obtained 1–3 days before administration of the first vaccination. Postimmunization PBMC were obtained 3–4 wk after the second vaccination. FNA samples were obtained within 2 days of the collection of the relative PBMC samples.

  • b Tumor aspirates underwent no peptide exposure (No pep). Quantitative PCR performed directly on fresh sample. Values represent copies of IFN-γ mRNA per 104 copies of CD8 mRNA. Post values twice pre values are underlined.

  • c Fold increase (Fold inc) for tumor monitoring = Post values divided by Pre values. Fold increases ≥2 are underlined.

  • d Values represent copies of gp100 mRNA per 104 copies of α-actin mRNA.